Drug intelligence / Profile preview

Formulation B

Development stage: Unknown
Lead developer: Northwestern University
Modality: Small Molecules
Administration: Topical

Overview

Formulation B is an experimental topical cream containing 1.0% salicylic acid, developed by Northwestern University for the treatment of mild to moderate acne vulgaris. It was evaluated in a split-face, paired-comparison pilot study (NCT01141023) to assess its safety and efficacy relative to another 1.0% salicylic acid formulation (Formulation A). As a beta-hydroxy acid, salicylic acid functions as a keratolytic agent by promoting the desquamation of the stratum corneum and penetrating the pilosebaceous unit to dissolve comedones. This action helps to clear existing acne lesions and prevent the formation of new ones by reducing follicular occlusion.

Other names: Salicylic acid 1.0% cream

Beyond the preview

Go deeper on Formulation B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Formulation B.

Explore the full profile